ZA200804874B - Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses - Google Patents

Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses

Info

Publication number
ZA200804874B
ZA200804874B ZA200804874A ZA200804874A ZA200804874B ZA 200804874 B ZA200804874 B ZA 200804874B ZA 200804874 A ZA200804874 A ZA 200804874A ZA 200804874 A ZA200804874 A ZA 200804874A ZA 200804874 B ZA200804874 B ZA 200804874B
Authority
ZA
South Africa
Prior art keywords
flaviviruses
serotypes
prophylactic
proteins
methods
Prior art date
Application number
ZA200804874A
Other languages
English (en)
Inventor
Chinea Santiago Glay
Huerta Galindo Vivian
Martin Dunn Alejandro Miguel
Gavilondo Cowley Jorge Victor
Fleitas Salazar Noralvis
Guirola Cruz Osmany
Gil Valdes Jeovanis
Zulueta Morales Aida
Hermida Cruz Lisset
Ayala Avila Marta
Gonzalez Roche Diamile
Paez Meireles Rolando
Toledo Mayora Patricia Gabriela
Sarria Nunez Monica
Musacchio Lasa Alexis
Mazola Reyes Yuliet
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of ZA200804874B publication Critical patent/ZA200804874B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200804874A 2005-11-22 2008-06-04 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses ZA200804874B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050229A CU23586A1 (es) 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Publications (1)

Publication Number Publication Date
ZA200804874B true ZA200804874B (en) 2009-04-29

Family

ID=38983663

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804874A ZA200804874B (en) 2005-11-22 2008-06-04 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses

Country Status (13)

Country Link
US (1) US20090312190A1 (xx)
EP (1) EP1958959A2 (xx)
JP (1) JP2009524581A (xx)
KR (1) KR20080080137A (xx)
CN (1) CN101360758A (xx)
AR (1) AR058215A1 (xx)
AU (1) AU2006317350A1 (xx)
BR (1) BRPI0618865A2 (xx)
CA (1) CA2630629A1 (xx)
CU (1) CU23586A1 (xx)
RU (1) RU2008125077A (xx)
WO (1) WO2007059715A2 (xx)
ZA (1) ZA200804874B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5448447B2 (ja) * 2006-05-26 2014-03-19 国立大学法人京都大学 ケミカルゲノム情報に基づく、タンパク質−化合物相互作用の予測と化合物ライブラリーの合理的設計
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CN101921310B (zh) * 2009-06-15 2014-03-12 温州医学院 登革病毒特异性hla-a2限制性表位肽及应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US20130203655A1 (en) * 2010-02-12 2013-08-08 Margaret Kielian Methods for preventing or treating viral infection
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
CN102168058B (zh) * 2010-11-30 2013-01-16 湖南师范大学 一种抗肿瘤靶向工程菌和菌剂及其制备方法
CN102824633A (zh) * 2011-06-16 2012-12-19 中国人民解放军军事医学科学院微生物流行病研究所 一种四价登革病毒亚单位疫苗及其制备方法和应用
BR112014020052B8 (pt) 2012-02-16 2023-04-18 Vlp Therapeutics Llc Partícula do tipo vírus, composições, método de produção de anticorpo e uso da referida partícula
CN108912215A (zh) * 2012-04-02 2018-11-30 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
US20150265695A1 (en) * 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
AU2013299986B2 (en) * 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
CN103116022A (zh) * 2013-01-23 2013-05-22 广西壮族自治区兽医研究所 快速检测猪乙型脑炎抗体试纸条及其制备方法
CA2907597A1 (en) * 2013-05-07 2014-11-13 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules
SG11201510617WA (en) * 2013-06-26 2016-01-28 Univ North Carolina Methods and compositions for dengue virus vaccines
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
SG11201701669PA (en) 2014-09-11 2017-04-27 Vlp Therapeutics Llc Flavivirus virus like particle
US10501552B2 (en) 2015-01-26 2019-12-10 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
CN111971397A (zh) * 2018-02-14 2020-11-20 耶鲁大学 用于调节trem或treml蛋白的组合物及其使用方法
KR102301130B1 (ko) * 2018-12-27 2021-09-15 주식회사 이뮨메드 뎅기출혈열 진단 키트
CN110007067A (zh) * 2019-03-11 2019-07-12 江苏理工学院 一种蛋白质分子对接检测装置
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
AU4556597A (en) 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CU22666A1 (es) * 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
DE69841690D1 (de) 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
WO1999015692A2 (en) 1997-09-23 1999-04-01 Bavarian Nordic Research Institute A/S Dengue virus antigens and treatment of dengue fever
DE69942525D1 (de) 1998-09-02 2010-08-05 Us Government Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
DE602006015807D1 (de) * 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm

Also Published As

Publication number Publication date
KR20080080137A (ko) 2008-09-02
US20090312190A1 (en) 2009-12-17
WO2007059715A8 (es) 2008-02-14
RU2008125077A (ru) 2009-12-27
AR058215A1 (es) 2008-01-23
BRPI0618865A2 (pt) 2011-09-13
CN101360758A (zh) 2009-02-04
JP2009524581A (ja) 2009-07-02
AU2006317350A1 (en) 2007-05-31
WO2007059715A3 (es) 2007-10-18
WO2007059715A2 (es) 2007-05-31
CU23586A1 (es) 2010-10-30
EP1958959A2 (en) 2008-08-20
CA2630629A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
ZA200804874B (en) Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
IL257622B (en) Methods and preparations for the treatment of persistent infections
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
IL189329A (en) The vaccine against dengue fever virus infection has been used and used
EP1865967A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
EP1879515A4 (en) OSTEOSYNTHETIC IMPLANTS AND METHODS OF USE AND MANUFACTURE
EP1928453A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING RENAL DISEASES
EP1968505A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF BONE FRACTURES
NO20054711D0 (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
GB0722578D0 (en) Methods and compositions for delaying the release of treatment chemicals
EP1954295A4 (en) COMPOSITION WITH EFFECT ON THE TREATMENT AND PREVENTION OF DRY EYES
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
IL195272A0 (en) Methods and compositions for the treatment of viral infections
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
EP1734975A4 (en) VEGETABLE THERAPY FOR THE TREATMENT OF FOOD ALLERGIES
IL187405A0 (en) Methods and compositions for the treatment of pain
DE602006006861D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
EP1765331A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
ZA200709443B (en) Methods for the treatment of substance abuse and dependence
GB0504657D0 (en) Compositions and methods of treatment